Journal article
Post-operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of pre-operative treatment and elective indication
M He, J Lovell, BL Ng, J Spillane, D Speakman, MA Henderson, M Shackleton, DE Gyorki
Journal of Surgical Oncology | Published : 2015
DOI: 10.1002/jso.23938
Abstract
Introduction Metastasectomy can provide durable disease control for selected patients with metastatic melanoma. Vemurafenib is a BRAF kinase inhibitor which has demonstrated significant improvement in disease-specific survival in patients with metastatic melanoma with a BRAF gene mutation. This study examined the efficacy and safety of metastasectomy during treatment with vemurafenib. Methods A retrospective review was performed of all patients receiving vemurafenib at Peter MacCallum Cancer Centre. Patient records were reviewed to identify patients undergoing surgery within 30 days of vemurafenib therapy. Descriptive statistics and survival analysis were performed. Results Nineteen patients..
View full abstractGrants
Funding Acknowledgements
The authors thank Ann Fennessy for assistance in identifying patients for the study. Mark Shackleton was supported by the Australian National Health and Medical Research Council, Pfizer Australia and the Victorian Endowment for Science, Knowledge and Innovation.